摘要
急性心肌梗死合并心源性休克是难治性心血管危重疾病,尽管机械循环支持及血运重建等技术不断发展并应用于临床,但心源性休克依然具有极高的死亡风险。左西孟旦作为一种新型正性肌力药及钙离子增敏剂,主要作用是正性肌力和扩张血管。近年来,相关动物试验及临床研究表明,在心血管系统中,左西孟旦已不仅用于失代偿性心力衰竭的医治,越来越多的证据表明该药物对重症患者的心、肺、肾等脏器具有一定的保护作用,是一种更具优势的心脏保护药物。本文主要根据近几年的文献报道,归纳整理了左西孟旦的作用机制及其在急性心肌梗死合并心源性休克中的研究进展,以期为急性心肌梗死合并心源性休克患者提供更多的诊疗思路。
Acute myocardial infarction with cardiac shock is a critical circulatory system disease that is difficult to cure.Despite the development and clinical application of mechanical circulation support and revascularization techniques,cardiogenic shock is still a high risk of death.As a new positive inotropic agent and calcium sensitizer,levosimendan has the dual effect of positive inotrophy and vasodilation.In recent years,related animal and clinical studies have confirmed that levosimentan is a more advantageous heart protective drug,as levosimentan has not only been used in the treatment of decompensated heart failure in cardiovascular system diseases,but also had certain protective effect on the lung,kidney and other organs of critically ill patients.Based on recent literature reports,this review summarized the mechanism of levosimendan and its research progresses in acute myocardial infarction complicated with cardiogenic shock to provide more diagnosis and treatment ideas for cardiogenic shock.
作者
樊星星
席荣
侯文杰
牛晓琳
FAN Xing-xing;XI Rong;HOU Wen-jie;NIU Xiao-lin(Xi’an Medical College,Xi’an 710068,Shaanxi,China;Shaanxi University of Chinese Medicine,Xianyang 712046,Shaanxi,China;Department of Cardiology,Tangdu Hospital,Air Force Medical University,Xi’an 710038,Shaanxi,China)
出处
《心脏杂志》
2025年第5期587-590,共4页
Chinese Heart Journal
基金
陕西省重点研发项目(2022SF-600)。
